Research programme: therapeutic angiogenesis - 7TM Pharma
Latest Information Update: 04 Nov 2017
At a glance
- Originator 7TM Pharma
- Class Neuropeptides
- Mechanism of Action Neuropeptide Y2 receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Obesity; Peripheral arterial disorders; Wounds
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Peripheral-arterial-disorders in Denmark
- 04 Nov 2017 No recent reports of development identified for preclinical development in Wounds in Denmark
- 01 Dec 2005 Preclinical trials in Obesity in Denmark (unspecified route)